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S566 I. J. Radiation Oncology d Biology d Physics Volume 72, Number 1, Supplement, 2008For each image set, the following distances were calculated: (1) fiducial to fiducial, (2) COMFids to each individual fiducial, and
(3) COMFids to the prostate COM. The magnitudes of these distances in CT0 were compared to those in CTSim to evaluate migra-
tion.
Results: Comparison of 45 inter-seed measurements (3 for each patient) from CT0 with those from CTSim demonstrated the ab-
solute value of inter-seed migration averaged 0.9 mm with a standard deviation (SD) of 0.8 mm. The average accounting for
both increases and decreases in inter-seed distances between CT0 and CTSim was near zero (0.1 mm with a SD of 1.3 mm), indi-
cating no significant systematic increase or decrease during this period. Similarly, the absolute value of the change in distance be-
tween the COMFids and each individual seed averaged 1.2 mm with a SD of 0.9 mm, and the average of increases and decreases in
this distance was 0.0 mm with SD of 1.5 mm. 95% of measured changes in the magnitude of inter-seed and COMFids-to-seed dis-
tances were less than 3 mm, and 90% were less than 2 mm. The absolute value of the change in distance between the COMFids and
the prostate COMwas on average 2.6 mmwith a SD of 2.1 mm. This variation is reasonable considering the uncertainty in prostate
localization.
Conclusions: Inter-seed distances changed by less than 1mm on average in the first week after implantation. The consistency of the
distance between the COMFids and the prostate COM demonstrates the stability of the seeds within the prostate. CT simulation for
treatment planning may occur on the day of fiducial implantation without concern for significant migration of the seeds.
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Purpose/Objective(s): We aimed at comparing the dose distribution of HDR brachytherapy and IMRT in prostate cancer.
Materials/Methods: The tomodensitometric data of ten successive patients treated with HDR brachytherapy for prostate cancer
were recovered for the dosimetric intercomparison. The Nomos-Corvus treatment planning system (TPS) was used for IMRT plan-
ning while dose distribution for HDR brachytherapy was calculatedwith the Brachyvision TPS. A theoretical dose of 10 Gy applied
by 2 Gy per fraction (EQD2) was prescribed on the PTV in the IMRT approach. We selected an a/b ratio of 1.5 Gy to calculate
a biological equivalent unique dose for HDR brachytherapy (5.22 Gy). The dose was normalized in order to allow 95% coverage of
the PTV. The dose-volume histograms were calculated for PTV and organs at risk (OARs). For these, doses were converted to
EQD2, considering an a/b ratio of 3 Gy. Differences between the obtained dose-distributions were compared with a two-sided
Student’s t test.
Results:Dose heterogeneity is more pronounced with HDR brachytherapy with a mean dose to the PTV of 23.8 Gy as compared to
10.5 Gy with IMRT. Cold spots are similar with both methods: 7.93 Gy and 8.17 Gy, respectively, with IMRT and HDR brachy-
therapy (p = 0.6). The rectal dose is reduced by HDR brachytherapy as 0.5 cc of the rectum received 5.9 Gy as compared to 10.2 Gy
with IMRT (p\0.0001). 8.08 Gy was delivered to 20% of the rectal volume with IMRT as compared to 2.74 Gy with HDR bra-
chytherapy (p\0.0001). The same observation favoring HDR brachytherapy is made for the bladder: 20% of the organ received
7.11 Gy with IMRT but 1.76 Gy with HDR brachytherapy (p\0.0001). The maximal dose delivered to the urethra is increased by
HDR brachytherapy to 13.4 Gy as compared to 11.1 Gywith IMRT butmean dose andminimal dose on the urethra are significantly
lower with HDR brachytherapy (p\0.0025). The volume of normal tissues receiving 1 Gy was reduced by a factor 8 with HDR
brachytherapy (p\ 0.0001).
Conclusions: HDR brachytherapy allows high hyperdosage sleeves inside the PTV while sparing dramatically the OARs as com-
pared to IMRT. The lower number of expected secondary cancers will thus favor brachytherapy use in exclusive or boosting ra-
diation programs, particularly for younger patients.
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Purpose/Objective(s): To use fractional integral target dose to obtain the fraction of energy absorbed by the prostate from integral
dose, which is an indication of ‘‘radiation delivery efficiency’’ in brachytherapy. Also to introduce a parameter that shows the frac-
tion of excess energy absorbed in the prostate. Those parameters can be used to aid the clinical choice of isotopes.
Materials/Methods: A total of 15 boost therapy implant cases (5 for each isotope) are utilized for this comparison. The TRUS
images are obtained intra-operatively using B&K Ultrasound unit in 5 mm steps. The planning parameters are defined according
to RTOG 0232 guidelines. The prescription doses are: 85 Gy for Cs-131, 108 Gy for I-125 and 100 Gy for Pd-103. The seed
strengths employed are: 1.8 U (Cs-131), 1.42 U (Pd-103) and 0.279-0.356 U (I-125). The prostate volume ranges from 25 to
50 cc. Planning goals are: V100 95%, D90100%, and prostatic urethra D10 150%. Dose calculations are performed using Vari-
seed (ver7.1, VMS, Palo Alto, CA) planning system using AAPM TG-43 formalism. All plans are evaluated to insure the planning
goals are met. Uniformity (V200), D90 for urethra, and D30 for rectum are also evaluated. Integral target dose are obtained by mul-
tiplying the prostate volume V with mean dose Dmean. Total integral dose is obtained by adopting the point source model from
AAPM TG43. The integral dose E delivered by a single source with unit activity is the integration of 4Pi r2 D(r)/r2 dr times
1.44T1/2. Let A be the total activity implanted, the total integral dose will be AE. The fractional integral target dose the prostate
receives is defined as DmeanV/AE. We also define a parameter (Dmean-mPD)V/AE that indicates the fraction of excess energy ab-
sorbed in the prostate. This parameter shows the amount of energy that is more than needed to achieve theminimum peripheral dose
(mPD).
